WALTHAM, Mass., May 25, 2022–(BUSINESS WIRE)–ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the rapidly expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that presentations following by company management at the next event the lectures will be webcast:
A webcast of each presentation will be accessible via the “Investors and Media” section of the Company’s website, www.immunogen.com. After the live webcast, a replay will be available at the same location.
ABOUT THE IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerance profiles, we aim to disrupt cancer progression and provide our patients with more good days. This is what we call our commitment to TARGET A BETTER NOW™.
Find out who we are, what we do and how we do it at www.immunogen.com.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220525005263/en/
INVESTOR AND MEDIA RELATIONS